A Phase 2/3 interventional study of Air-sham and Zelpultide alfa in Bronchopulmonary Dysplasia, sponsored by Airway Therapeutics, Inc.. Recruiting at 49 sites in 8 countries. Open to participants aged 0 Minutes to 96 Hours. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Airway Therapeutics, Inc. · Phase 2/3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a randomized, parallel-group, double-blind, placebo-controlled multicenter phase 2b/3 study with an adaptive seamless design.
The goal fo this study is to determine if an investigational drug, Zelpultide Alfa, can reduce the occurrence of Bronchopulmonary Dysplasia (BPD) in extremely premature babies.
The study comprises 2 parts:
In Part 1, the study subjects will be randomized with a 1:1:1 allocation ratio to either :
In Part 1, all three arms will be evaluated descriptively to support dose selection based on safety, tolerability, and exploratory efficacy signals. Upon completion of Part 1, the DSMC will recommend which Phase 2b dose ("selected dose") to progress into Part 2 to the Study Steering Committee, which will decide the dose for Part 2 (Phase 3). A sample size reassessment will be performed after Part 1 completion.
In Part 2, the selected dose of zelpultide alfa will be compared against placebo (air-sham) in a confirmatory analysis on the primary and key secondary endpoints. The study subjects will be randomized with a 1:1 allocation ratio to either:
In both parts, treatment will be administered intratracheally. Participants will receive up to 7 administrations of zelpultide alfa at (4mg/kg or 6 mg/kg) or air-sham in 24 h intervals while the subjects are still intubated per standard of care.
362 studies on the registry are indexed under Bronchopulmonary Dysplasia; 84 are open to participants now.
This study's planned enrollment of 366 is above the median of 66 across 244 interventional studies indexed under Bronchopulmonary Dysplasia.
Browse Bronchopulmonary Dysplasia studies →Airway Therapeutics, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Major apparent congenital abnormalities impacting cardio and pulmonary function identified before randomization, such as, but not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In addition to the preterm neonate standard of care, the subjects randomized to this treatment arm will receive up to 7 administrations of zelpultide alfa at 4 mg/kg (birth weight) in 24 h intervals while the subjects are still intubated.
Drug: Zelpultide alfa
In addition to the preterm neonate standard of care, approximately 1 mL of air drawn into a dosing syringe will be administered up to 7 times to neonate subjects randomized to the control (placebo) arm, following the same means and intervals as in the treatment arm.
Other: Air-sham
In addition to the preterm neonate standard of care, the subjects randomized to this treatment arm will receive up to 7 administrations of zelpultide alfa at 6 mg/kg (birth weight) in 24 h intervals while the subjects are still intubated.
Drug: Zelpultide alfa
Room air for intratracheal administration
Reconstituted Zelpultide alfa for intratracheal administration
Also known as: AT-100, rhSP-D
Incidence of grade 2 or grade 3 Bronchopulmonary Dysplasia (BPD) or death
BPD is defined and graded based on the classification according to Jensen et al., 2019 (2019 PMID: 30995069)
Time frame: Week 36 Post Menstrual Age (PMA)
Ventilator-free days
A ventilator-free day is defined as a natural calendar day without being on invasive mechanical ventilation (ie, invasive ventilation via ETT or tracheostomy); tracheostomy will be treated as all invasive ventilation.
Time frame: From birth to 36 weeks Post Menstrual Age (PMA)
Incidence of grade 2 or grade 3 Bronchopulmonary Dysplasia (BPD)
Time frame: Week 36 Post Menstrual Age (PMA)
Incidence of death
Time frame: Week 36 Post Menstrual Age (PMA)
Incidence of grade 2 or grade 3 Bronchopulmonary Dysplasia (BPD) or death assessed on 3 consecutive days at week 36 PMA
BPD is defined and graded based on the classification according to Jensen et al., 2019 (2019 PMID: 30995069)
Time frame: Week 36 Post Menstrual Age (PMA)
The proportion of subjects with no Bronchopulmonary Dysplasia (BPD), grade 1, grade 2, or grade 3 BPD
BPD is defined and graded based on the classification according to Jensen et al., 2019 (2019 PMID: 30995069)
Time frame: Week 36 Post Menstrual Age (PMA)
The proportion of subjects with no Bronchopulmonary Dysplasia (BPD), grade 1, grade 2, or grade 3 BPD assessed on 3 consecutive days at week 36 PMA
BPD is defined and graded based on the classification according to Jensen et al., 2019 (2019 PMID: 30995069)
Time frame: Week 36 Post Menstrual Age (PMA)
Ventilator-free days
A ventilator-free day is defined as a natural calendar day without being on invasive mechanical ventilation (ie, invasive ventilation via ETT or tracheostomy); tracheostomy will be treated as all invasive ventilation.
Time frame: From birth to day 28 of life
Total average days on supplemental oxygen
Time frame: From birth to 36 Weeks Post Menstrual Age (PMA)
Total average days on continuous positive airway pressure (CPAP) or high flow nasal cannula (HFNC)
Time frame: From birth to week 36 Post Menstrual Age (PMA)
Extubation rate
Time frame: Study Day 7
Average preductal oxygen saturation measured by oxygen saturation to fraction of inspired oxygen ratio (SF)
Time frame: From Study Days 1 to 7
Average preductal oxygen saturation measured by oxygen saturation index (OSI)
Time frame: From Study Days 1 to 7
Incidence of grade 2 or grade 3 Bronchopulmonary Dysplasia (BPD) or death
BPD is defined and graded based on the classification according to Jensen et al., 2019 (2019 PMID: 30995069)
Time frame: Week 40 Post Menstrual Age (PMA)
Incidence of grade 2 or grade 3 Bronchopulmonary Dysplasia (BPD)
BPD is defined and graded based on the classification according to Jensen et al., 2019 (2019 PMID: 30995069)
Time frame: Week 40 Post Menstrual Age (PMA)
The proportion of subjects with no Bronchopulmonary Dysplasia (BPD), grade 1, grade 2, or grade 3 BPD
BPD is defined and graded based on the classification according to Jensen et al., 2019 (2019 PMID: 30995069)
Time frame: Week 40 Post Menstrual Age (PMA)
Incidence of grade 2 or grade 3 Bronchopulmonary Dysplasia (BPD) or death after excluding subjects with death at ≤ 14 days postnatal age
BPD is defined and graded based on the classification according to Jensen et al., 2019 (2019 PMID: 30995069)
Time frame: Week 36 and week 40 Post Menstrual Age (PMA)
Ventilator-free days
A ventilator-free day is defined as a natural calendar day without being on invasive mechanical ventilation (ie, invasive ventilation via ETT or tracheostomy); tracheostomy will be treated as all invasive ventilation.
Time frame: From birth to week 40 Post Menstrual Age (PMA)
Survival at 6, 12 and 24 months corrected age
Time frame: 6, 12 and 24 month corrected age
Average number of hospitalizations and days in hospital
Time frame: 6 and 12 months corrected age
Incidence of chronic respiratory morbidity
Time frame: 12 month corrected age
Incidence of neurodevelopmental disability among survivors
Time frame: 24 months corrected age
Severity and frequency of treatment-emergent adverse events (TEAEs) or treatment-emergent serious adverse events (TESAEs)
Time frame: From start of treatment through week 36 Post Menstrual Age (PMA) or hospital discharge, whichever comes first
Immunogenicity analysis
Determination of anti-SP-D antibodies in blood at day 28 of life compared to baseline), assessed in a subset of 60 patients
Time frame: Day 28 of life
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Mar 2028, 37 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zelpultide alfa
Airway Therapeutics, Inc.